文献速递白血病

达沙替尼或尼洛替尼停用于慢性髓性白血病:STOP 2G-TKI 研究的中期分析

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
PubMed 文献 · Blood · 2016-12-08

STOP 2G-TKI 是一项多中心观察性研究,评估一线或后续达沙替尼/尼洛替尼停用。60 例至少 TKI 治疗 3 年且达 MR4.5 并至少前 2 年 BCR-ABL1 转录本不可测的患者,中位随访 47 个月,12 与 48 个月无治疗缓解率分别为 63.33% 与 53.57%,无进展至晚期,复发者重启治疗后均重获 MMR 和 MR4.5。

要点

  • 停用一线或后续达沙替尼/尼洛替尼后 12 与 48 个月无治疗缓解率分别为 63.33% 与 53.57%。
  • 26 例(43.3%)发生分子学复发,中位复发时间 4 个月(范围 1-38)。
  • 停药后 3 个月失去 MR4.5 可预测后续无法维持 MMR。

核心结论

  • 停用一线或后续第二代 TKI 可获得有前景的无治疗缓解率,且无安全性担忧。
  • 鼓励进一步研究以更好地定义使患者最有机会维持停用第二代 TKI 的条件。

研究设计与样本

  • STOP 2G-TKI 为多中心观察性研究,评估慢性髓性白血病中第二代 TKI 停用。
  • 纳入一线或后续达沙替尼或尼洛替尼治疗至少 3 年、达分子学反应 4.5(MR4.5)且至少前 2 年 BCR-ABL1 转录本不可测的患者。
  • 本次中期分析报告 60 例患者,最短随访 12 个月(中位 47,范围 12-65)。

主要发现

  • 26 例(43.3%)发生分子学复发,定义为失去主要分子学反应(MMR)。
  • 复发发生于中位 4 个月(范围 1-38)。
  • 12 与 48 个月分子学复发累积发生率分别为 35%(95%CI 24.79%-49.41%)与 44.76%(95%CI 33.35%-59.91%)。
  • 12 与 48 个月无治疗缓解率分别为 63.33%(95%CI 51.14%-75.53%)与 53.57%(95%CI 40.49%-66.65%)。
  • 单因素分析中,既往次优反应或 TKI 耐药是唯一与显著更差结局相关的基线因素。

关键数值与推荐

  • 停药后 3 个月失去 MR4.5 的界标分析显示可预测后续无法维持 MMR。
  • 无治疗阶段无进展至晚期慢性髓性白血病,所有复发患者重启治疗后均重获 MMR 和 MR4.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STOP second generation (2G)-tyrosine kinase inhibitor (TKI) is a multicenter observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid leukemia (CML). Patients receiving first-line or subsequent dasatinib or nilotinib who stopped therapy after at least 3 years of TKI treatment and in molecular response 4.5 (MR4.5) with undetectable BCR-ABL1 transcripts for the 2 preceding years at least were eligible for inclusion. This interim analysis reports outcomes of 60 patients with a minimum follow-up of 12 months (median 47, range: 12-65). Twenty-six patients (43.3%) experienced a molecular relapse defined as the loss of a major molecular response (MMR). Relapses occurred after a median time of 4 months (range: 1-38). Cumulative incidences of molecular relapse by 12 and 48 months were 35% (95% confidence interval [CI], 24.79% to 49.41%) and 44.76% (95% CI, 33.35% to 59.91%), respectively. Treatment-free remission (TFR) rates at 12 and 48 months were 63.33% (95% CI, 51.14% to 75.53%) and 53.57% (95% CI, 40.49% to 66.65%), respectively. In univariate analysis, prior suboptimal response or TKI resistance was the only baseline factor associated with significantly worse outcome. A landmark analysis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain MMR later on. During the treatment-free phase, no progression toward advanced phase CML occurred, and all relapsing patients regained MMR and MR4.5 after restarting therapy. In conclusion, discontinuation of first-line or subsequent 2G-TKI yields promising TFR rates without safety concerns. Further research is encouraged to better define conditions that will offer patients the highest chance to remain free from 2G-TKI therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2016. PMID: 27932374. doi:10.1182/blood-2016-09-742205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。